Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer

被引：9

作者：

Boucher, Andree ^{[1
]}

Ezzat, Shereen ^{[2
]}

Hotte, Sebastien ^{[3
]}

Rachinsky, Irina ^{[4
]}

Rajaraman, Murali ^{[5
]}

Ruether, Dean ^{[6
]}

Wiseman, Sam M. ^{[7
]}

Brierley, James ^{[8
]}

Ho, Cheryl ^{[9
]}

Krzyzanowska, Monika ^{[2
]}

Lamond, Nathan ^{[10
]}

Massicotte, Marie-Helene ^{[11
]}

Joseph, Shereen ^{[12
]}

Herscovitch, Kassey ^{[12
]}

Sikora, Lindsey ^{[13
]}

Winquist, Eric ^{[14
,15
]}

机构：

[1] Univ Montreal, Dept Endocrinol, Montreal, PQ, Canada

[2] Univ Toronto, Dept Med, Toronto, ON, Canada

[3] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

[4] Univ Western Ontario, Dept Med Imaging, Div Nucl Med, London, ON, Canada

[5] Dalhousie Univ, Dept Radiat Oncol, Halifax, NS, Canada

[6] Univ Calgary, Dept Oncol, Calgary, AB, Canada

[7] Univ British Columbia, Dept Surg, Vancouver, BC, Canada

[8] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada

[9] Univ British Columbia, Dept Med, Vancouver, BC, Canada

[10] Dalhousie Univ, Div Med Oncol, Halifax, NS, Canada

[11] Univ Sherbrooke, Dept Med, Div Endocrinol, Sherbrooke, PQ, Canada

[12] Kataka Med Commun, 4035 St Ambroise,Suite 300, Montreal, PQ, Canada

[13] Univ Ottawa, Hlth Sci Lib, Ottawa, ON, Canada

[14] Univ Western Ontario, Dept Oncol & Otolaryngol, London, ON, Canada

[15] Univ Western Ontario, Dept Head & Neck Surg, London, ON, Canada

来源：

ORAL ONCOLOGY | 2021年 / 121卷

关键词：

Thyroid Neoplasms; Thyroid Neoplasms Head and Neck Neoplasms; Iodine Radioisotopes; Protein Kinase Inhibitors; Radioactive iodine; Resistant; Refractory; Differentiated thyroid cancer; Lenvatinib; Sorafenib; MULTITARGETED KINASE INHIBITORS; WHOLE-BODY SCAN; I-131; THERAPY; ASSOCIATION GUIDELINES; APPROPRIATE TIME; SORAFENIB; LENVATINIB; METASTASES; DOSIMETRY; PAPILLARY;

D O I：

10.1016/j.oraloncology.2021.105477

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Radioactive iodine-resistant differentiated thyroid cancer (RAIRTC) is an aggressive form of thyroid cancer that is uncommon and heterogeneous in its clinical behavior. With the emergence of more effective systemic therapy, the need for guidance in decision-making was recognized and a consensus committee of national experts was assembled. The consensus committee consisted of 13 clinicians involved in treating RAIRTC from across Canada and included endocrinologists, nuclear medicine physicians, surgeons, and radiation and medical oncologists. Domains of interest were identified by consensus, and evidence gathered using systematic reviews. Consensus recommendations for the diagnosis and management of RAIRTC were developed. It was recognized that the rarity of RAIRTC in practice and heterogeneous patterns of thyroid cancer care could limit access to effective therapy for some RAIRTC patients. This document offers guidance to manage RAIRTC patients in a multidisciplinary manner.

引用

页数：9

共 50 条

[1] Overview of Radioactive Iodine-Resistant Differentiated Thyroid Cancer
Sherman, Steven I.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (07) : 3 - 5
[2] Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
Fullmer, Tanner
Cabanillas, Maria E. E.
Zafereo, Mark
[J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
[3] Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy
Schechter, Rebecca B.
Nagilla, Madhavi
Joseph, Loren
Reddy, Poluru
Khattri, Arun
Watson, Sydeaka
Locati, Laura D.
Licitra, Lisa
Greco, Angela
Pelosi, Giuseppe
Carcangiu, Maria Luisa
Lingen, Mark W.
Seiwert, Tanguy Y.
Cohen, Ezra E. W.
[J]. CANCER LETTERS, 2015, 359 (02) : 269 - 274
[4] OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS
Jasim, Sina
Iniguez-Ariza, Nicole M.
Hilger, Crystal R.
Chintakuntlawar, Ashish V.
Ryder, Mabel M.
Morris, John C., III
Bible, Keith C.
[J]. ENDOCRINE PRACTICE, 2017, 23 (10) : 1254 - 1261
[5] Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer
Ibrahim, Eiman Y.
Busaidy, Naifa L.
[J]. CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 151 - 158
[6] Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer
Balakirouchenane, David
Seban, Romain
Groussin, Lionel
Puszkiel, Alicja
Cottereau, Anne Segolene
Clerc, Jerome
Vidal, Michel
Goldwasser, Francois
Arrondeau, Jennifer
Blanchet, Benoit
Huillard, Olivier
[J]. THYROID, 2023, 33 (11) : 1327 - 1338
[7] Molecular predictors of response to sorafenib in patients with radioactive iodine-resistant advanced thyroid cancer.
Yarchoan, Mark
Cohen, Aaron Benjamin
Stopenski, Stephen J.
Haddad, Chia A.
Scott, Nathan L.
Ma, Cathy
Ransom, Evan R.
Troxel, Andrea B.
Feldman, Michael D.
Brose, Marcia S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer
Slonimsky, Einat
Tulchinsky, Mark
[J]. CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (31) : 3812 - 3827
[9] Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Schlumberger, Martin
Brose, Marcia
Elisei, Rosella
Leboulleux, Sophie
Luster, Markus
Pitoia, Fabian
Pacini, Furio
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 356 - 358
[10] Challenges in the evaluation and management of radioactive iodine-refractory differentiated thyroid cancer
Genco, Matthew T.
Yaqub, Abid
Jana, Suman
[J]. NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (07) : 743 - 745

← 1 2 3 4 5 →